Views: 1,395 | Downloads:
28
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Final Adult Height in Early Normal Pubertal Girls" Treated with Gonadotropin Releasing Hormone Agonists"
Wacharasindhu S 
,
Srivuthana MS ,
Aroonparkmongkol M ,
Supornsilchai V ,
Hiranrat P ,
Yodvisitsak V
,
Srivuthana MS ,
Aroonparkmongkol M ,
Supornsilchai V ,
Hiranrat P ,
Yodvisitsak V SUMARLEE SRIVUTHANA, MD*,
VI CHIT SUPORNSILCHAI, MD*,
VIRAPORN YODVISITSAK, MD**
Gonadotropin releasing hormone (GnRH) agonist has been used worldwide for the treat-
ment of central precocious puberty. However, the results on final adult height (FAH) are discrepant
in various studies especially in girls with normal early puberty. Fourteen girls with normal early puberty
who were treated with depot GnRH agonists 3.75 mg intramuscular (IM) monthly for a mean period
of 1.5
เธ‘
0.4 yr were retrospectively studied. The chronological age and bone age at the beginning of
treatment were 9.9
เธ‘
0.7 yr and 12.6
เธ‘
0.9 yr, respectively. When the treatment was stopped, all the
girls were followed-up until they reached their final adult heights. The results showed that the mean
FAH was 154.0
เธ‘
6.9 em, which was not significantly different from the predicted adult height (PAH)
at start of treatment, 153.1
เธ‘
6.2 m. All the girls were divided into 2 groups. Group A was girls who
had FAH-PAH at the start of treatment;?:: 1.5 em and group B, FAH-PAH at the start of treatment< 1.5
em. The authors found that only the duration of treatment was different between these 2 groups, 1. 7 เธ‘
0.3 yr in group A and 1.3 เธ‘ 0.3 yr in group B (p
=
0.015).
In conclusion, GnRH agonist cannot improve the final height outcome in girls with normal
early puberty. However, a longer period of treatment may improve the height prognosis.
Key word : Early Normal Puberty, GnRH Agonist, Final Adult Height
VI CHIT SUPORNSILCHAI, MD*,
VIRAPORN YODVISITSAK, MD**
Gonadotropin releasing hormone (GnRH) agonist has been used worldwide for the treat-
ment of central precocious puberty. However, the results on final adult height (FAH) are discrepant
in various studies especially in girls with normal early puberty. Fourteen girls with normal early puberty
who were treated with depot GnRH agonists 3.75 mg intramuscular (IM) monthly for a mean period
of 1.5
เธ‘
0.4 yr were retrospectively studied. The chronological age and bone age at the beginning of
treatment were 9.9
เธ‘
0.7 yr and 12.6
เธ‘
0.9 yr, respectively. When the treatment was stopped, all the
girls were followed-up until they reached their final adult heights. The results showed that the mean
FAH was 154.0
เธ‘
6.9 em, which was not significantly different from the predicted adult height (PAH)
at start of treatment, 153.1
เธ‘
6.2 m. All the girls were divided into 2 groups. Group A was girls who
had FAH-PAH at the start of treatment;?:: 1.5 em and group B, FAH-PAH at the start of treatment< 1.5
em. The authors found that only the duration of treatment was different between these 2 groups, 1. 7 เธ‘
0.3 yr in group A and 1.3 เธ‘ 0.3 yr in group B (p
=
0.015).
In conclusion, GnRH agonist cannot improve the final height outcome in girls with normal
early puberty. However, a longer period of treatment may improve the height prognosis.
Key word : Early Normal Puberty, GnRH Agonist, Final Adult Height
Download:
PDF